231 related articles for article (PubMed ID: 27491027)
1. Detailed analysis of adverse events and surgical interventions in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients.
Noblett K; Benson K; Kreder K
Neurourol Urodyn; 2017 Apr; 36(4):1136-1139. PubMed ID: 27491027
[TBL] [Abstract][Full Text] [Related]
2. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
[TBL] [Abstract][Full Text] [Related]
3. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
[TBL] [Abstract][Full Text] [Related]
4. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2020 Apr; 39(4):1108-1114. PubMed ID: 32243625
[TBL] [Abstract][Full Text] [Related]
5. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
[TBL] [Abstract][Full Text] [Related]
6. Baseline symptom severity and therapeutic success in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients.
Noblett K; Berg KC; Kan F; Siegel S
Neurourol Urodyn; 2018 Jun; 37(5):1667-1671. PubMed ID: 29635879
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of clinical performance and safety for the rechargeable InterStim Micro device in overactive bladder subjects: 6-month results from the global postmarket ELITE study.
Goudelocke C; Xavier K; Pecha B; Burgess K; Perrouin-Verbe MA; Krlin R; Michaels J; Shah S; Peyronnet B; Zaslau S; Champs M; Papi B; Bittner K; Elterman D; Nitti V
Neurourol Urodyn; 2023 Apr; 42(4):761-769. PubMed ID: 36917003
[TBL] [Abstract][Full Text] [Related]
8. Remotely programmed sacral neuromodulation for the treatment of patients with refractory overactive bladder: a prospective randomized controlled trial evaluating the safety and efficacy of a novel sacral neuromodulation device.
Zhang Y; Zhang P; Tian X; Chen G; Li Y; Zhang Y; Xu Z; Wei Z; Zhang W; Ma L; Shi B; Liao L; Wang J
World J Urol; 2019 Nov; 37(11):2481-2492. PubMed ID: 30809700
[TBL] [Abstract][Full Text] [Related]
9. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation.
Siegel S; Noblett K; Mangel J; Bennett J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Zylstra S; Kan F; Berg KC
J Urol; 2018 Jan; 199(1):229-236. PubMed ID: 28709886
[TBL] [Abstract][Full Text] [Related]
10. Three-year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated With Sacral Neuromodulation.
Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Thiery E
Urology; 2016 Aug; 94():57-63. PubMed ID: 27131966
[TBL] [Abstract][Full Text] [Related]
11. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe M; Elneil S
Neurourol Urodyn; 2018 Feb; 37(S2):S9-S16. PubMed ID: 29315785
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for explantation due to infection after sacral neuromodulation: a multicenter retrospective case-control study.
Myer ENB; Petrikovets A; Slocum PD; Lee TG; Carter-Brooks CM; Noor N; Carlos DM; Wu E; Van Eck K; Fashokun TB; Yurteri-Kaplan L; Chen CCG
Am J Obstet Gynecol; 2018 Jul; 219(1):78.e1-78.e9. PubMed ID: 29630890
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and adverse events of sacral nerve stimulation for overactive bladder: A systematic review.
Siddiqui NY; Wu JM; Amundsen CL
Neurourol Urodyn; 2010; 29 Suppl 1():S18-23. PubMed ID: 20419795
[TBL] [Abstract][Full Text] [Related]
14. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
15. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
Tilborghs S; De Wachter S
Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
[TBL] [Abstract][Full Text] [Related]
16. Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation?
Amin K; Moskowitz D; Kobashi KC; Lee UJ; Lucioni A
J Urol; 2019 May; 201(5):973-978. PubMed ID: 30694936
[TBL] [Abstract][Full Text] [Related]
17. Five-year Results from the Prospective, Multicenter, Observational SOUNDS Study of Patients with Overactive Bladder Treated with the InterStim System for Sacral Neuromodulation.
Chartier-Kastler E; Le Normand L; Ruffion A; Saussine C; Braguet R; Rabut B; Ragni E; Perrouin-Verbe MA; Pierrevelcin J; Rousseau T; Gamé X; Tanneau Y; Dargent F; Biardeau X; Graziana JP; Stoica G; Brassart E; Fourmarier M; Yaghi N; Capon G; Ferchaud J; Berrogain N; Peyrat L; Pecoux F; Bryckaert PE; Karsenty G; Song S; Keller DUJ; Cornu JN
Eur Urol Focus; 2023 Sep; 9(5):765-772. PubMed ID: 37019729
[TBL] [Abstract][Full Text] [Related]
18. Sacral Neuromodulation with the InterStim System for Overactive Bladder: 3-Year Results from the French Prospective, Multicenter, Observational SOUNDS Study.
Chartier-Kastler E; Normand LL; Ruffion A; Saussine C; Braguet R; Rabut B; Ragni E; Perrouin-Verbe MA; Pierrevelcin J; Rousseau T; Gamé X; Tanneau Y; Dargent F; Biardeau X; Graziana JP; Stoica G; Brassart E; Fourmarier M; Yaghi N; Capon G; Ferchaud J; Berrogain N; Peyrat L; Pecoux F; Bryckaert PE; Melotti A; Abouihia A; Keller DUJ; Cornu JN
Eur Urol Focus; 2022 Sep; 8(5):1399-1407. PubMed ID: 34334342
[TBL] [Abstract][Full Text] [Related]
19. Programming settings and recharge interval in a prospective study of a rechargeable sacral neuromodulation system for the treatment of overactive bladder.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe M; Elneil S
Neurourol Urodyn; 2018 Feb; 37(S2):S17-S22. PubMed ID: 29336058
[TBL] [Abstract][Full Text] [Related]
20. First-in-human implantation of a mid-field powered neurostimulator at the sacral nerve: Results from an acute study.
van Kerrebroeck PEVA; Reekmans M; van Koeveringe GA; Yeh AJ; Fayram TA; Sharan AD; Comiter CV
Neurourol Urodyn; 2019 Aug; 38(6):1669-1675. PubMed ID: 31107559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
